Interview with Wolf Kupatt, Managing Director, Baxter Germany
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
Address: Edisonstraße 4
85716 Unterschleißheim
,Germany
Tel: +49 89 31701-0
Baxter International Inc. Is an American health care company headquartered in Deerfield, Illinois. The company primarly focuses on products treating Hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company has world-wide sales of 13.3billion dollars in sales, across three manufacturing divisions :BioScience, producing blood plasma proteins; Medication Delivery producing intravenous therapy products and liquids; and Renal producing equipment for dialysis and the treatment of kidney disorders. The company is also involved in the production of a vaccine for the H1N1 influenza.The company started operations in Germany through its office in Munich in 1960 counting with now over 1,000 employees in the country. Partner of hospitals worldwide, Baxter does not disappoint in Germany with its presence in the hospital care, but also with home care haemophilia vaccines and renal replacement therapy.
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
The latest news from German pharma, including looming drug pricing reform, Boehringer Ingelheim’s EUR 640 million acquisition of a Kyowa Kirin autoimmune drug, and BioNTech’s updated revenue guidance. Also covered…
Rainer Westermann of European life science venture capital lobby group, the Life Sciences Acceleration Alliance, lays out a policy roadmap for how innovative European pharma can continue to grow and…
Once a little-known mRNA pioneer, BioNTech became a household name with its COVID-19 vaccine developed alongside Pfizer. But the German biotech is now pursuing an even bigger transformation — and…
A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut…
After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to…
European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
The latest news from German pharma, including why Merck KGaA is looking to life science M&A; positive outlooks for Bayer and STADA; BioNTech’s move into the AI lab assistant space…
A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in…
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
See our Cookie Privacy Policy Here
